GLP-1 TV · News & media · views checked Oct 2026
Hims & Hers offers cheaper weight-loss pill in a shock to Novo
Our summary
According to the video, shares of Novo Nordisk fell again on Thursday after the online health firm Hims & Hers said it will sell a compounded version of Novo's new Wegovy weight loss pill. The report says the price would be about $100 below the brand name price. Novo responded that it would take legal action against Hims & Hers.
General education as published by the channel. Not medical advice, and not an endorsement.
Where semaglutide pill costs least today
The three cheapest partner programs for semaglutide pill, all in per month, checked weekly. Brand Wegovy pill and compounded versions are different products; each row says which it is.
What else the video covers
The video lays out the pricing. Hims & Hers said it will charge a $49 introductory price for the first month. The price then rises to $99 a month for customers who buy a five-month plan and pay upfront, and the report says a three-month subscription costs more. The video places the news after Novo warned on Wednesday that pricing pressure on its weight loss medicines was unprecedented and cut its forecast, which sent its European shares down 17%. It says Novo, like rival Eli Lilly, has had to cut prices in the US, its biggest market, under pressure from President Donald Trump. Novo launched its Wegovy pill last month at a discount to the injection, aimed at customers who pay directly on its website.
The report also covers the history between the two companies. They had a partnership in 2025 that let Hims & Hers offer injectable Wegovy, but they parted ways. Novo said Hims & Hers wrongly marketed copycat versions, and Hims & Hers accused Novo of trying to control how its clinicians make decisions. The video says the compounded pill uses semaglutide, the same active ingredient as Novo's product, and that the FDA issued a warning in September about marketing claims for such drugs. It closes with Novo's statement that it will act to protect patients and its intellectual property.
Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.
Takeaways
The main points, in the order they come up. Tap a time to play from there.
- 0:01 According to the video, Novo Nordisk shares fell after Hims & Hers announced a compounded version of the Wegovy pill about $100 below the brand price, and Novo said it would take legal action.
- 0:15 The report says Hims & Hers will charge $49 for the first month, rising to $99 a month on a prepaid five-month plan, with a higher price for a three-month plan.
- 0:32 The video says the news followed Novo's Wednesday warning of unprecedented pricing pressure, a lower forecast and a 17% drop in its European shares.
- 0:50 According to the report, Novo and Eli Lilly have both cut US prices under pressure from President Donald Trump, and Novo launched its pill last month at a discount to the injection.
- 1:10 The video describes the split of the 2025 Novo and Hims & Hers partnership, with Novo citing wrongly marketed copycats and Hims & Hers citing Novo's control over clinician decisions.
- 1:36 The report says the compounded pill is made from semaglutide and that the FDA warned in September that same-ingredient marketing claims are misleading because compounded drugs are not FDA approved.
What the video says
As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.
- Medication
- Wegovy
- Prices mentioned
- $99 a month
- Who is speaking
- News or media
In their words
"illegal mass compounding that poses a significant risk to patient safety"
Questions this video answers
How much does the Hims & Hers compounded weight loss pill cost?
According to the video, Hims & Hers will offer a $49 introductory price for the first month. The price rises to $99 a month for people who buy a five-month plan and pay upfront, and the report says a three-month subscription costs more. The video says this is about $100 less than the brand name price.
Why did Novo Nordisk shares fall after the Hims & Hers announcement?
The video says shares dropped again after Hims & Hers announced the cheaper compounded pill and Novo said it would take legal action. It adds that Novo had warned a day earlier of unprecedented pricing pressure and lowered its forecast, which sent its European shares down 17%.
What does the FDA say about compounded semaglutide marketing?
According to the video, the FDA issued a warning in September about marketing of the drug. It stated that claims of the same active ingredient as Ozempic and Wegovy are misleading because compounded drugs are not FDA approved.
What is Novo Nordisk's response to the Hims & Hers compounded pill?
The video says Novo called the action illegal mass compounding that poses a significant risk to patient safety. Novo said it would take action to protect patients, its intellectual property and the US drug approval framework.
Videos on the same question
The closest videos in the library by what is said in them, not by title.
HIMS Slides 25% After NVO Sues Company Over Generic GLP-1 PillsAccording to the video, a Schwab Network Morning Trade Live segment covers Hims & Hers pulling its compounded semaglutide pill after Novo Nordisk threatened legal action.
Novo Nordisk strikes deal for Hims to sell Wegovy and OzempicAccording to the video, Novo Nordisk announced on Monday that it has agreed to sell Wegovy and Ozempic through the US telehealth platform run by Hims and Hers.
Novo Nordisk CEO Sees Weight-Loss Market Expanding as Wegovy Pill Goes on SaleIn this Bloomberg interview, Novo Nordisk CEO Mike Doustdar discusses the launch of the Wegovy pill in the U.S.
Novo CEO Says Wegovy Pill Is Safe and Will Be Widely AvailableIn this Bloomberg Television interview, the host speaks with Mike Doustdar, the CEO of Novo Nordisk, about the launch of the Wegovy pill.
Wegovy Deal Makes Cofounder Of Hair Loss Pill Seller Hims, A BillionaireAccording to the video, Andrew Dudum, co-founder and CEO of the online pharmacy Hims and Hers, has become a billionaire after a strong earnings report and a new deal to sell a popular weight loss drug.
Hims & Hers launches into Canada as country prepare for generic GLP-1 weight loss drugsAccording to the video, a CNBC report says Hims & Hers Health is expanding into Canada by completing an all-cash acquisition of Livewell, a Canadian digital health provider known for weight loss care.
Read next
Our guides closest to what this video covers, with prices checked weekly.
- The Wegovy pill: what each dose costs, and how it compares with the pen
Wegovy is now sold as a daily tablet as well as a weekly injection, and the tablet self-pays cheaper. Novo's published prices run $149 a month at 1.5 mg, $199 at 4 mg and $299 at 9 mg and 25 mg. The $149 offer on 4 mg ended on 31 August 2026. There are also three different semaglutide pills on the market now, which is the thing most pages about this have not caught up with.
- How much does Wegovy cost: the pen, the pill, insured, cash, Medicare and compounded, in one table
Wegovy costs six different amounts depending on who is paying. A commercial plan that covers it brings it to $25 a month with Novo's card, capped at $100 of savings. Medicare covers it for $50 a month through the GLP-1 Bridge until the end of 2027. Cash, the pen is $349 a month at every dose, $199 for the first two fills if you are new, and $399 for the 7.2 mg HD pen; the pill is $149, $199 or $299 by strength. Compounded semaglutide, the same molecule without FDA approval, starts at $69 on our board. This page holds all six with their conditions and their sources.
- Wegovy pill vs injection: the same semaglutide, two schedules, two price lists
The Wegovy pill and the Wegovy pen are the same drug, semaglutide. The pill is one tablet a day on an empty stomach with a little water; the pen is one injection a week at any time. Novo's cash price is $149 to $299 a month for the pill by strength and $349 for the pen. In separate placebo trials the top tablet dose and the pen produced similar average weight loss.
Find more like it
Cost and insurance
Up next
More from this collection
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.























